(Q50218409)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Ignacio González-Garcia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

11

J H Beijnen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

author name string

L van Andel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

H Rosing

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

S Munt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

B Miguel-Lillo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

M M Tibben

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

N de Vries

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

A H M de Vries Schultink

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

J H M Schellens

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

publication date

23 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

9 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

589-598

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-017-0432-5

9 April 2020

exact match

0 references

cites work

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Cyclic depsipeptides as potential cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0432-5

The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28111728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Human radiolabeled mass balance studies: objectives, utilities and limitations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28111728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-017-0432-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28111728%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference